BC Innovations | Nov 18, 2019
Distillery Therapeutics

The transcription factors ID1 and ID3 as targets for AMD and retinopathy

DISEASE CATEGORY: Ophthalmic INDICATION: Age-related macular degeneration (AMD); retinopathy of prematurity A Memorial Sloan Kettering Cancer Center team led by Angiogenex Inc. CEO Robert Benezra showed that inhibiting the transcription factors ID1 and ID3 could...
BC Innovations | Sep 24, 2015

Full speed AMED

In the five months since the Japan Agency for Medical Research and Development (AMED) opened its doors, the organization has created a network of 80 Japanese medical schools and hospitals to predict what the future...
BC Innovations | Aug 6, 2009
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Leukemia Inhibitor of DNA binding 3 (ID3) Studies in cell culture suggest that increasing ID3 expression could be useful for treating acute lymphoblastic leukemia (ALL)....
BioCentury | Apr 10, 2006

Lion chronicles

Lion chronicles Weekly stock price for Lion (FSE:LIO) tracked against selected events since its IPO in August 2000. Y-axis on logarithmic scale A. 8/10/00 - Raises $182M in an IPO, listing on both the NASDAQ and...
BC Week In Review | Nov 17, 2003
Company News

PheneX AG, Lion bioscience deal

Nuclear receptor specialist PheneX acquired the assets that made up LIO's iD3 nuclear receptor drug discovery unit. LIO discontinued its iD3 group at the end of 2002. PheneX AG , Heidelberg, Germany   Lion bioscience AG...
BC Extra | Nov 13, 2003
Company News

PheneX buys Lion bioscience discovery assets

Nuclear receptor specialist PheneX (Heidelberg, Germany) acquired from Lion bioscience (FSE:LIO; LEON) the assets that made up LIO's iD3 nuclear receptor drug discovery unit. LIO discontinued its iD3 group at the end of 2002. PheneX's...
BioCentury | Oct 14, 2002

Europe's restructuring

Europe's restructuring Date Company Staff cuts Notes 6/30 cash 1H op loss Years cash pre-cut 08/23 Bavarian Nordic (A) 13% to 65 Aims to reduce operating costs by $5.3M in 2003. Dropping in-house development of...
BioCentury | Oct 14, 2002

Europe's tight corset

European companies are starting to feel the pinch from both the capital markets and the slowdown in pharma partnering. Over the last three months, Europe has seen only 13 pharma deals - with none of the...
BC Week In Review | Sep 9, 2002
Company News

Lion bioscience bioinformatics, genomics news

LEON said it will terminate its iD3 drug discovery business by the end of the year in order to focus on its bioinformatics business. LEON expects the move to save it up to $20 million...
BioCentury | Sep 9, 2002

Ebb & Flow

After slipping 2% last week, the BioCentury 100 index shed 8% over the past two weeks, sucking a lot of air out of the biotech rally that began on July 12. The group remains up...
Items per page:
1 - 10 of 15